TalkMed Group (5G3) Stock Overview

TalkMed Group Limited, an investment holding company, provides medical oncology, stem cell transplants, and palliative care services in Singapore, China, Hong Kong, Vietnam, India, Australia, and internationally. It operates through three segments: Oncology Services; Stem Cell Related Products and Services; and Cellular and Gene Therapy Related Products and Services. The company offers medical oncology services in the areas of breast, colon, lung, liver, biliary and pancreatic, gastro-intestinal, head and neck, genitourinary and gynaecological, and haematology malignancies and brain cancers, as well as lymphoma and leukaemia. It also provides palliative care services comprising cancer pain management, discharge and home care planning, advance care planning, and end-of-life care planning; and ancillary health services, such as CANSCREEN, a screening program that provides screening for individuals at a risk of getting cancer. In addition, the company is involved in the goods and services related to cellular and gene therapy; specialist doctors and clinical staff services; and healthcare management services. It operates a network of nine clinics. The company was founded in 1997 and is based in Singapore. TalkMed Group Limited is a subsidiary of Ladyhill Holdings Pte. Ltd.